Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RICU NTM study

ABSTRACT: RICU NTM study

PROVIDER: PRJEB61771 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR11411000.fastq.gz	Fastqsanger.gz
	ERR11411001.fastq.gz	Fastqsanger.gz
	ERR11411002.fastq.gz	Fastqsanger.gz
	ERR11411003.fastq.gz	Fastqsanger.gz
	ERR11410977.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 27

Similar Datasets

NGS RICU study 2024

Project description:NGS RICU study 2024

| PRJEB73552 | ENA

NTM & Healthy Donor Immunology & Genomics

Project description:NTM & Healthy Donor Immunology & Genomics

| PRJNA853847 | ENA

NTM & Healthy Donor Immunology & Genomics

Project description:NTM & Healthy Donor Immunology & Genomics

| PRJNA853848 | ENA

Pseudomonas cerasi strain:NTM-B-30

Project description:Pseudomonas cerasi strain:NTM-B-30 Genome sequencing

| PRJNA925447 | ENA

Mycolicibacterium parafortuitum strain:Panama NTM 1

Project description:Mycolicibacterium parafortuitum strain Panama NTM 1 genome sequencing

| PRJNA1113557 | ENA

Pseudomonas cerasi strain:NTM-B-29

Project description:Pseudomonas cerasi strain:NTM-B-29 Genome sequencing and assembly

| PRJNA925443 | ENA

Xanthomonas arboricola pv. corylina strain:NTM-B-28

Project description:Xanthomonas arboricola pv. corylina strain:NTM-B-28 Genome sequencing

| PRJNA934755 | ENA

Immunologic features of nontuberculous mycobacterial pulmonary disease based on spatially resolved whole transcriptomes

Project description:The immunologic features of nontuberculous mycobacterial pulmonary disease (NTM-PD) are largely unclear. This study investigated the immunologic features of NTM-PD using digital spatial profiling techniques. Lung tissues obtained from six patients with NTM-PD between January 1, 2006, and December 31, 2020, at Seoul National University Hospital were subjected to RNA sequencing. Cores from the peribronchial and fibrotic stromal areas were stained with CD3, CD68, and DNASyto13, and gene expression at the whole-transcriptome level was quantified using PCR amplification and Illumina sequencing. Lung tissues from four patients with bronchiectasis collected during the same period were used as controls. The RNA sequencing results were validated using immunohistochemistry (IHC) in another cohort (30 patients with NTM-PD and 15 patients with bronchiectasis). NTM-PD exhibited distinct gene expression patterns in T cells and macrophages. Gene set enrichment analysis revealed that pathways related to antigen presentation and processing were upregulated in NTM-PD, particularly in macrophages. Macrophages were more prevalent and the expression of genes associated with the M1 phenotype (CD40 and CD80) was significantly elevated. Although macrophages were activated in the NTM-PD group T cell activity was unaltered. Notably, expression of the costimulatory molecule CD28 was decreased in NTM-PD. IHC analysis showed that T cells expressing Foxp3 or TIM-3, which facilitate the regulatory functions of T cells, were increased. From these, NTM-PD exhibits distinct immunologic signatures characterized by the activation of macrophages without T cell activation.

2024-08-06 | GSE273714 | GEO

Whole blood gene expression to predict susceptibility to nontuberculous mycobacterial pulmonary disease in adults with cystic fibrosis

Project description:Background: Patients with cystic fibrosis (CF) have an elevated lifetime risk of infection and disease caused by nontuberculous mycobacteria (NTM). Currently, there is no method to predict whether patients with cystic fibrosis will develop disease related to non-tuberculous mycobacteria. In non cystic fibrosis populations, several genetic susceptibility factors have been described. In this study, we examined whether patients with cystic fibrosis demonstrate a similar pattern of genetic susceptibility and explored host immune-related biomarkers predictive of NTM pulmonary disease (NTM-PD). Methods: We evaluated whole blood gene expression using bulk RNA-seq in a cohort of CF patients at the time of first isolation of NTM. Differential gene expression was compared in patients who did (n = 12) vs. did not (n= 30) develop NTM-PD following first NTM growth. Results: No differences in demographics or composition of white blood cell sample populations at the time of sample collection were identified between groups. There were no significant differences in the expression of genes previously reported to confer susceptibility to NTM-PD in non-CF populations. However, CF patients who went on to develop NTM-PD had higher expression of genes involved in the interferon ( and ), tumor necrosis factor, and IL6 STAT3 JAK pathways. Conclusion: Patients with CF who develop NTM-PD have increased expression of genes involved in innate immunity, in contrast to non-CF populations where these responses seem to be suppressed.

2022-12-14 | GSE205161 | GEO

homo sapiens

Project description:NTM Human Microbiome and Inflammation Study

| PRJNA418131 | ENA